Group 1 - The Hong Kong innovative drug sector experienced a significant surge, with 9 out of the top 10 performing ETFs being related to innovative drugs [2] - The Hong Kong innovative drug ETF (513120) rose by 3.17%, leading the market [2] - The approval of innovative drugs has increased significantly, with 43 new drugs approved in the first half of the year, a 59% year-on-year increase [2] Group 2 - The short-term bond ETF (511360) recorded a trading volume of 225.09 billion, the highest among all ETFs [4] - On August 4, the total net inflow for all ETFs was 37.72 billion, with significant inflows into several ETFs [4] - The market is expected to maintain a fluctuating upward trend, with a focus on sectors like AI, military, and innovative drugs [5][6]
市场交投显著活跃 港股创新药主题ETF厚积薄发
Zhong Guo Zheng Quan Bao·2025-08-05 21:05